Diomidis Kozyrakis

Dr. Diomidis Kozyrakis

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2013 in Asian Journal of Andrology
Verified
Journal Article
Open access
NMNikos Mertziotis
Nikos Mertziotis
DKDiomidis Kozyrakis
Diomidis Kozyrakis
EBElias Bogris
Elias Bogris
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.

4 August 2011 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
DKDiomidis Kozyrakis
Diomidis Kozyrakis
CPConstantina Petraki
Constantina Petraki
IPIoannis Prombonas
Ioannis Prombonas
AGAlkiviadis Grigorakis
Alkiviadis Grigorakis
GKGeorgios Kanellis
Georgios Kanellis
DMDimitrios Malovrouvas
Dimitrios Malovrouvas

8 February 2018 in Urologia Internationalis
Verified
Journal Article
Closed access
PDF file
DKDiomidis Kozyrakis
Diomidis Kozyrakis
SPStefanos Perikleous
Stefanos Perikleous
SCStyliani-Elissavet Chatzistamou
Styliani-Elissavet Chatzistamou
DKDimitris Kateris
Dimitris Kateris
GSGeorgios Soukias
Georgios Soukias
IDIoannis Dimitriadis
Ioannis Dimitriadis
Introduction: To present the incidence of bacterial colonization on ureteral double J stents (DJS); isolate the uropathogens; define the rate of multi-resistant b

1 January 2009 in Cases Journal
Verified
Journal Article
Open access
PDF file
DKDiomidis Kozyrakis
Diomidis Kozyrakis
PPPanteleimon Papadaniil
Panteleimon Papadaniil
SSStefanos Stefanakis
Stefanos Stefanakis
EPEfstathios Pantazis
Efstathios Pantazis
AGAlkiviadis Grigorakis
Alkiviadis Grigorakis
DMDimitrios Malovrouvas
Dimitrios Malovrouvas
Neuroendocrine small cell carcinoma of the urinary tract is rarely encountered and very few cases have been reported in the literature. Herein we describe a case of small cell malignancy located contemporarily in the ureter and the bladder.

1 December 2017
Verified
Journal Article
Open access
AKAnastasios Karatzas
Anastasios Karatzas
DPDionyssios Paridis
Dionyssios Paridis
DKDiomidis Kozyrakis
Diomidis Kozyrakis
VTVassilios Tzortzis
Vassilios Tzortzis
MSMichael Samarinas
Michael Samarinas
TKTheofilos Karachalios
Theofilos Karachalios

26 December 2018 in Advances in Urology
Verified
Journal Article
Open access
PDF file
DKDiomidis Kozyrakis
Diomidis Kozyrakis
DPDionyssios Paridis
Dionyssios Paridis
SPStefanos Perikleous
Stefanos Perikleous
KMKonstantinos Malizos
Konstantinos Malizos
AZAnastasios Zarkadas
Anastasios Zarkadas
ATAntonios Tsagkalis
Antonios Tsagkalis
Purpose. Prostate cancer (PCa) is one of the most frequently diagnosed malignancies worldwide. Hormonal deprivation therapy is a well-established treatment for locally advanced or metastatic diseases but exposes patients to the risk of osteoporosis and fragility fractures. Furthermore, the tropism of the PCa cells to osseous metastases increases the incidence of skeletal-related events (SREs). Methods. A nonsystematic review of the international literature was performed in respect to the use of osteoclast inhibitors zoledronic acid (ZA) and denosumab (DEN) in PCa patients. Results. DEN and ZA have proved their efficacy in preventing osteoporosis and bone mass loss in patients treated with hormonal therapy with no proven superiority of one agent over the other. However, the effectiveness in reducing fragility fractures has been proved only for DEN so far. In metastatic-free castrate-sensitive high-risk PCa patients, ZA has not shown any efficacy in preventing osseous metastasis, and evidence is lacking in favor or against the use of DEN. The use of osteoclasts inhibitors had no evident positive effect in overall and disease-specific survival in this group of patients. In advanced castrate-refractory malignancy, DEN has shown clinical superiority over ZA in preventing new SRE but not in overall survival. Conclusion. Superiority of DEN over ZA has been proved only in advanced castrate refractory disease in terms of preventing new SRE. In the rest of the cases, the selection of either agent should be based on the clinical condition of each patient and the cost of the treatment.